TORONTO and HAIFA, Israel, June 04, 2025 (GLOBE NEWSWIRE) — NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”) is pleased to announce that on May 22, 2025, it presented new manufacturing process data at the 4th annual meeting of the Israeli Society for Extracellular Vesicles Research (“ISEVR”), a conference dedicated to cutting-edge exosome science. Additionally, the Company will seek shareholder approval of its amended and restated omnibus incentive plan (the “Omnibus Plan”) at the its upcoming annual general and special meeting being held on June 18, 2025 (the “Meeting”).
Manufacturing Process Validation
The Company’s presentation showcased promising early data on the viability and potency of cells from its proprietary Master Cell Bank (“MCB”). The MCB represents a valuable and key strategic asset in advancing good manufacturing practices (“GMP”)-compliant manufacturing of exosomes for the Company’s lead therapeutic candidate, ExoPTEN, as well as for its subsidiary, Exo-Top Inc. (“Exo-Top”). “The findings suggest strong economic potential, indicating that the MCB may support an extended number of production batches maximizing its value and utility”, commented Dr. Dr. Tali Kizhner, Research and Development Director of NurExone.